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Significantly Low Effective Dose from 18FDG PET/CT Scans
Using Dose Reducing Strategies: “Lesser is Better”
Maseeh uz Zaman1*, Nosheen Fatima2, Areeba Zaman3, Unaiza Zaman3, Rabia
Tahseen3
Abstract
Background: Fluorodeoxyglucose (18FDG) PET/CT imaging has become an important component of the
management paradigm in oncology. However, the significant imparted radiation exposure is a matter of growing
concern especially in younger populations who have better odds of survival. The aim of this study was to estimate
the effective dose received by patients having whole body 18F-FDG PET/CT scanning as per recent dose reducing
guidelines at a tertiary care hospital. Materials and Methods: This prospective study covered 63 patients with
different cancers who were referred for PET/CT study for various indications. Patients were prepared as per
departmental protocol and 18FDG was injected at 3 MBq/Kg and a low dose, non-enhanced CT protocol (LDNECT) was used. Diagnostic CT studies of specific regions were subsequently performed if required. Effective
dose imparted by 18FDG (internal exposure) was calculated by using multiplying injected dose in MBq with
coefficient 1.9×10-2 mSv/MBq according to ICRP publication 106. Effective dose imparted by CT was calculated
by multiplying DLP (mGy.cm) with ICRP conversion coefficient “k” 0.015 [mSv / (mG. cm)]. Results: Mean age
of patients was 49 ±18 years with a male to female ratio of 35:28 (56%:44%). Median dose of 18FDG given was
194 MBq (range: 139-293). Median CTDIvol was 3.25 (2.4-6.2) and median DLP was 334.95 (246.70 - 576.70).
Estimated median effective dose imparted by 18FDG was 3.69 mSv (range: 2.85-5.57). Similarly the estimated
median effective dose by low dose (non-diagnostic) CT examination was 4.93 mSv (range: 2.14 -10.49). Median
total effective dose by whole body 18FDG PET plus low dose non-diagnostic CT study was 8.85 mSv (range:
5.56-13.00). Conclusions: We conclude that the median effective dose from a whole body 18FDG PET/CT in our
patients was significantly low. We suggest adhering to recently published dose reducing strategies, use of ToF
scanner with CT dose reducing option to achieve the lower if not the lowest effective dose. This would certainly
reduce the risk of second primary malignancy in younger patients with higher odds of cure from first primary
cancer.
Keywords: 18FDG - PET/CT - CT dose index - dose length product - effective dose - low dose non-enhanced
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Introduction
Introduction of hybrid positron emission tomography
and computerized tomography (PET/CT) has allowed
concurrent functional and morphological imaging with
better sensitivity, specificity and diagnostic accuracy (Von
Schulthess et al., 2006). For these reasons PET/CT has
become an important component of management paradigm
in oncology as it helps in diagnosis, staging, restaging,
response evaluation and prognostication (Zaman et al.,
2014). CT component in hybrid PET/CT is used for
attenuation correction, anatomical correlation without or
with diagnostic quality imaging.
In recent era, due to arrival of very effective new
therapies, overall survival of many cancers has improved
especially lymphoma and childhood cancers (Milana

et al., 2015; Uslu et al., 2015). These patients on an
average do have at least 2-3 PET/CT scans during their
management and in view of better survival especially
in younger population radiation dose incurred by
these procedures is a major concern. CT component
contributes more than 60% of effective dose to patients
and increase the life time attributable risk (LAR) for
second primary malignancy (Jallow et al., 2016). To
address this issue, recent guidelines have recommended
use of low dose non-contrast enhanced CT for attenuation
correction and anatomical mapping and smaller doses
of fluorodeoxyglucose (18FDG) (Boellaard et al., 2015).
At the moment in Pakistan, there are four FDG
based PET/CT facilities catering a population of more
200 million. Our facility being the youngest and the
only accredited tertiary healthcare PET/CT facility by
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Joint Commission is strictly following these recent dose
minimizing recommendations. To the best of our search,
there is no local data regarding the radiation dose to
patients who have FDG based PET/CT as per recently
published protocols (Graham et al., 2015).
The objective of this study was to estimate the effective
dose received by patients having whole body 18FDG PET/
CT scanning as per recent dose reducing guidelines at a
tertiary care hospital.

were referred for 18FDG PET/CT examinations for
their oncological workup (staging 40%, restaging 11%,
response evaluation 30%, Follow-up 17%; Surveillance
02%). Out of these 63 patients, 20 (32%) had lymphoma,
09 (14%) had gastrointestinal, 06 (10%) had breast, 5 (8%)
ovarian, 5 (8%) had carcinoma of unknown primary, 4
(6%) each for kidney/urinary bladder and mouth and 10
(16%) miscellaneous cancers. Nineteen (30%) patients
have had at least 1 PET/CT examination in past. Mean age

Materials and Methods
This was a prospective study performed at the PET/
CT facility of Aga Khan University Hospital, Karachi,
Pakistan from March-April 2016. As per departmental
protocol, patients were fasted for at least 4 hours but
encouraged maintaining hydration with plain water.
Diluted oral gastrografin (10 cc in liter water) was given to
patient to drink at least 1 hour prior to radiotracer injection.
Fasting blood glucose <200 mg/dl was mandatory and
test were rescheduled if it ≥200 mg/dl. Patients were
positioned on bed/recliner in uptake room and 18FDG
was injected intravenously (3 MBq/kg) followed by flush
with 10 cc of normal saline. During uptake period (50-75
minute) patients were encouraged to take 500 ml of plain
water with gastrografin and were asked to void bladder 5
minutes prior the PET/CT imaging.
PET/CT images were acquired using Toshiba
Celesteoin with 16 slice CT (Toshiba Med Corp, Japan).
The PET scanner has lutetium oxyorthosilicate (LSO)
crystal detectors with a time of flight (ToF) resolution time
<450 picoseconds. A scout view was acquired to plan the
study, followed by a non-contrast enhanced CT (NECT)
protocol in cranio-caudal direction for the purpose
of anatomical localization and attenuation correction
(Tube Potential: 120 kVp; Tube Current: upto 120 mAs;
Rotation Time 0.58 sec/rotation; Slice Thickness: 1mm).
Subsequently a three dimensional PET scan was acquired
at 3 min/bed position in a caudo-cranial direction.
The effective dose imparted by 18FDG (internal
exposure) was calculated by using coefficient
1.9×10-2milliSievert/Mega Becquerel(mSv/MBq)
according to ICRP publication 106 (ICRP 2008).To
estimate the effective dose from whole body CT scan
(external exposure), volume CT Dose Index (CTDIvol
in milliGray [mGy]) and Dose length Product (mGy.
cm) was directly obtained from the display screen of CT
workstation. Effective dose was calculated by multiplying
DLP (mGy.cm) with ICRP conversion coefficient “k”
0.015 [mSv / (mG. cm)] (Christner et al., 2010).

Results
Total 63 patients were included in this study who

Figure 1. Maximum Intensity Projection (MIP) Whole
Body PET Images Acquired with Lowest and Highest
Injected Doses of 18FDG
Table 1. Study Demographics
Variables
Mean Age ± SD
Male: Female
BMI (Kg/m2)
Previous PET-CT study
Median (range) dose of FDG (MBq)
Median (range) Mean Uptake Time
Mean FBS ± SD (mg/dl)
Median (range) CTDIvol
Median (range) DLP
Mean ± SD Hepatic SUVmean
Indication
Follow-up
Response Evaluation
Re-staging
Staging
Surveillance
Positive: Negative

N=63
49 ± 18
35:28 (56:44%)
24.42 ± 4.22
19 (30%)
194 (139-293)
70 (55-97)
111 ± 26
3.25 (2.4-6.2)
334.95
(246.70-576.70)
1.71 ± 0.44
11 (17%)
19 (30%)
07 (11%)
25 (40%)
01 (02%)
47:16 (75:25%)

SD=standard deviation; BMI=Body mass index; FDG=Fluorodeoxy
Glucose; FBS=Fasting Blood Sugar; CTDI=CT dose Index; DLP= Dose
Length Product; FU= Follow-up; RE= Response Evaluation; RS= ReStaging; SG= Staging; SV= Surveillance

Table 2. Effective Doses (mSv) Imparted by 18FDG, CT and Total by a PET/CT Study
Effective Dose by 18FDG
Median (mSv) (Range)
(1.9×10-2 mSv/MBq x MBq)
3.69 (2.85-5.57)

* k = 0.015 [mSv / (mG. cm)] (Christner et al., 2010)
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Effective Dose by CT
Median (mSv) (Range)
(DLP x “k”)*
4.93 (2.14-10.49)
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Total Effective Dose
Median (mSv) (Range)
8.85 (5.56-13.00)
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of patients was 49 ±18 years with a male to female ratio of
35:28 (56%:44%). Mean body mass index (BMI) of cohort
was 24.42 ± 4.22 Kg/m2. Mean fasting blood glucose
level was 111 ± 26 mg/dl. Median dose of 18FDG given
was 194 MBq (range: 139-293) and median uptake time
was 70 minute (range: 55-97). Mean hepatic standardized
uptake value (Hep SUVmean was 1.71 ± 0.44). PET/CT
examination was positive for 18FDG avid lesion (s) in 47
(75%) and negative in 15 (25%) cases. Median CTDIvol
was 3.25 (2.4-6.2) and median DLP was 334.95 (246.70
- 576.70) (Table 1).
Estimated median effective dose imparted by 18FDG
was 3.69 mSv (range: 2.85-5.57). Similarly the estimated
median effective dose by low dose (non-diagnostic) CT
examination was 4.93 mSv (range: 2.14 -10.49). Median
total effective dose by whole body 18FDG PET plus low
dose non-diagnostic CT study was 8.85 mSv (range: 5.5613.00) (Table 2).

Discussion
AIn recent days 18FDG based PET/CT imaging has
become an essential component of management paradigm
of many cancers (Ghotbi et al., 2007). A whole-body PET/
CT scanning is accompanied by substantial radiation dose
to the patients. We must be cognizant of importance of
potential risk from radiation exposure (i.e. second primary
malignancy) which must be gauged and understood so
that risk-benefit ratios can be assessed. This is particularly
important for younger population with better probability
of post-treatment survival. To address this issue, various
societies have issued appropriate use criteria, designed
imaging protocol and stressed upon using time of flight
(ToF) scanners which have better signal to noise ratio even
with lower injected dose of radiotracer. In our study, low
dose CT contributed about 60% of total effective dose
to the patients. This is slightly higher than a recently
published study in which CT contribution to total dose
was 54% as they have used higher injected dose of 18FDG
than our protocol (194 MBq vs 341 MBq) (Mahmud et al.,
2014). However, percentage contribution in our study was
significantly lower than another published study which
has a reported contribution of about 80% but they have
used a diagnostic rather than low dose CT scan (Huang
et al., 2009).
Median effective dose from PET study in this study
was 3.69 mSv for median injected 18FDG dose of 194
MBq. This dose is in accordance with recent European
Association of Nuclear Medicine (EANM) guidelines
(Boellaard et al., 2015). Effective dose delivered by 18FDG
in this study (i.e. 3.69 mSv) is significantly lower than
published studies (6.30 and 6.23 mSv) (Huang et al., 2009;
Mahmud et al., 2014). The most plausible explanations
for this disparity are (1) not following dose reducing
strategy; (2) well known concept of lower image quality
with lower radiotracer dose. However, it is now a wellestablished fact that shorter timing resolution of scanner
with ToF option ensures better signal to noise ratio, better
image quality, reduced imaging time and improve lesion
detectability (Surti 2015). Since the timing resolution of
our ToF scanner was<450 picoseconds, the image quality

was good even with low doses of 18FDG (Figure1). This
technical fact seeks attention of those nuclear medicine
users who are using higher doses of 18FDG despite of
having PET scanners with ToF option. Median effective
dose delivered by low dose non-enhanced CT in this study
was 4.93 mSv and this is significantly lower than effective
dose of 7.50 mSv reported in the published data (Mahmud
2014). The sentinel reason for this low CT effective dose
is availability of Adaptive Iterative Dose Reduction-3D
(AIDR-3D) technology in our CT scanner. These results
endorse the effectiveness of dose reducing strategies
recommended by current EANM guidelines which
encourage non-diagnostic CT as routine and discourage
the use of diagnostic quality CT with intravenous and oral
contrasts (Boellaard et al., 2015). We acquired diagnostic
CT study for a particular region of the body after acquiring
whole body PET/CT with a low-dose CT scan protocol
which is also regarded as a preferable option by recent
guidelines (Boellaard et al., 2015).
Median total effective dose imparted by PET/CT scan
in this study was 8.85 mSv. To the best of our search this
is the lowest reported dose imparted to patient by a single
PET/CT study. The lowest reported median effective
dose is 13.8 mSv using a low dose non-enhanced CT
(Mahmud 2014). While median effective doses reported
in other studies are 25 mSv (Brix et al., 2005) and 24.8
mSv (Chawla et al., 2010).
So this study draws our attention towards an important
fact that the effective dose from a whole body PET/CT
scan at our Institute is significantly lower if not lowest
(although we could not find any published data matching
this low dose). As mentioned above, reasons for this
significantly lower (if not lowest) are adherence to the dose
reducing strategies mentioned in recent guidelines and use
of a scanner with the lowest ToF and CT dose reducing
module. We are confident that reducing the effective dose
of a whole body PET/CT study would reduce the risk of
second primary malignancy in our younger patients who
have better odds of cure from their primary cancers like
lymphomas (Milana et al., 2015). Therefore, it is justifiable
to note that the radiation dose resulting from the PET/CT
scan has to be tailored to the needs of the study and the
impact of doing so should outweigh the radiation effect.
This study has some limitations and primary one is
smaller sample size. We are cognizant of the fact that
larger sample size would enhance the statistical strength
but these preliminary results from available data pave
the path for a larger prospective study. Second limitation
is use of simple strategies for effective dose calculation.
However, the coefficients factors used in this study have
been derived from well designed and validated studies.
Third limitation is that we did not calculate lifetime
attributable risk for cancer and would like to use in other
prospective study.
We conclude that the median effective dose from
a whole body 18FDG PET/CT in our patients was
significantly lower if not the lowest. We suggest adhering
to recently published dose reducing strategies, use of ToF
scanner with CT dose reducing option to achieve this
lower if not the lowest effective dose. This would certainly
reduce the risk of second primary malignancy in younger
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patients with higher odds of cure from first primary cancer.
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